Search
Close this search box.

Day: August 3, 2023

Zenas BioPharma annonce la publication d’une étude de phase 2 sur l’obéxélimab, un traitement expérimental pour la maladie liée aux IgG4 (ML-IgG4), dans The Lancet Rheumatology

L’étude a montré que l’obéxélimab produisait une amélioration clinique rapide, forte et soutenue, y compris une rémission clinique complète, chez la plupart des patients atteints de ML-IgG4 active Les résultats soutiennent la poursuite du développement de l’obéxélimab pour le traitement de la ML-IgG4 et potentiellement d’autres maladies auto-immunes à médiation

Zenas BioPharma Publica Fase 2 do Estudo Clínico do Obexelimabe, um Tratamento Investigativo da Doença Relacionada à IgG4 (IgG4-RD), no The Lancet Rheumatology

Estudo revelou que o obexelimabe produziu melhora clínica rápida, forte e sustentada, incluindo remissão clínica completa, na maioria dos pacientes com IgG4-RD ativa Os resultados apoiam o desenvolvimento contínuo do obexelimabe para o tratamento de IgG4-RD e potencialmente outras condições autoimunes mediadas por células B WALTHAM, Mass., Aug. 02, 2023

SWAG marks 55th Anniversary today

The Sports Writers Association of Ghana (SWAG) has marked its 55th anniversary as the umbrella for Sports Journalists in Ghana.Formed on 3rd August 1968, by a group of clear sighted, perceptive, and gnostic brains, the association has grown to impact G…

CDD-Ghana launches maiden Ghana Cities Monitor maiden report

The Ghana Centre for Democratic Development (CDD-Ghana) has launched its Ghana Cities Monitor (GCM) maiden report.The GCM, which was launched by Dr Edem Selormey, Director of Research, CDD-Ghana, is aimed at strengthening evidence-informed decision-mak…